Souhaitez-vous accéder aux communiqués récents ?

PARIS, 04 févr. 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 DateNombre total d’actions composant le capital socialNombre total de droits de...

PARIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...

REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

“Bioprocess Filtration: Global Markets” is estimated to grow from $8.4 billion in 2025 to $15.6 billion by 2030, at a CAGR of 13.1% from 2025 through 2030.

The acquisition expands scalable trial operations across real-world care settings

MONTRÉAL, 04 févr. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », « la Société », « nous » ou « notre ») (TSXV : LOVE) (OTCQX : LOVFF) (FRA : 8CB0), producteur verticalement...

Cannara completes C$6.3M non-brokered private placement at C$2.10/share with Phoenician; minor share sale by CEO Zohar Krivorot; AGM items approved.

Kneat will release its financial results for the quarter ended December 31, 2025 on February 25, 2026 and host a conference call on February 26, 2026.

aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis

Exploratory Phase 2a study showed consistent and clinically meaningful functional improvements across muscle strength, motor performance, and patient-reported outcomes in patients with...